DM 199

Drug Profile

DM 199

Alternative Names: DM-199; DM-99; Recombinant human tissue kallikrein-1 - DiaMedica Therapeutics; rhKLK-1 - DiaMedica

Latest Information Update: 05 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator DiaMedica
  • Developer DiaMedica; DiaMedica Therapeutics
  • Class Antidementias; Antihyperglycaemics; Antirheumatics; Insulin sensitisers; Nootropics; Recombinant proteins
  • Mechanism of Action Insulin receptor agonists; Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus
  • Phase I Diabetic nephropathies; Stroke
  • Preclinical Nephritis
  • Research Acute kidney injury
  • No development reported Alzheimer's disease; Rheumatoid arthritis; Type 1 diabetes mellitus

Most Recent Events

  • 01 May 2017 DiaMedica Therapeutics receives patent protection for DM 199 in USA
  • 20 Mar 2017 DiaMedica receives patent protection for DM 199 in European Union
  • 01 Mar 2017 DiaMedica and Novotech completes a phase I trial in Stroke (In volunteers) in Australia (NCT02868996)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top